2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
2 citations
,
March 2015 in “Expert opinion on orphan drugs” New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
1 citations
,
March 2024 in “Signal transduction and targeted therapy” NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
1 citations
,
February 2021 in “Farmacja Polska” Janus kinase inhibitors show promise in treating autoimmune skin diseases.
1 citations
,
January 2017 in “Springer eBooks” Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
February 2026 in “Colloids and Surfaces A Physicochemical and Engineering Aspects” JAK inhibitors can enter the skin through hair follicles using a unique pathway.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
July 2025 in “International Journal of Pharmaceutical Sciences Review and Research” Individualized treatment and psychological support improved the patient's quality of life and appearance despite medication side effects.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
March 2025 in “International Journal of Trichology” Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
New therapies like JAK inhibitors, PRP, and stem cell treatments show promise for better alopecia management.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
December 2024 in “Cureus” Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
May 2024 in “Frontiers in Immunology” Type-2 immunity may influence skin diseases and could be targeted for treatment.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
April 2022 in “Biomedicine & Pharmacotherapy” CXCL12 protein slows down hair growth through its receptor CXCR4. Blocking this can potentially increase hair growth.
February 2021 in “Journal of pharmaceutical and biological sciences” No cure exists for alopecia areata, and treatments are personalized.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
January 2025 in “FASKES Jurnal Farmasi Kesehatan dan Sains” Erythrina subumbrans leaves may help treat hair loss.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.